Alliancebernstein L.P. Acquires 32,923 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Alliancebernstein L.P. raised its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 13.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 275,263 shares of the biotechnology company's stock after acquiring an additional 32,923 shares during the quarter. Alliancebernstein L.P. owned approximately 0.12% of ADMA Biologics worth $4,721,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. HighTower Advisors LLC raised its position in ADMA Biologics by 41.1% in the third quarter. HighTower Advisors LLC now owns 87,471 shares of the biotechnology company's stock valued at $1,748,000 after purchasing an additional 25,492 shares during the last quarter. National Bank of Canada FI acquired a new position in ADMA Biologics in the 3rd quarter valued at approximately $35,000. Barclays PLC raised its stake in shares of ADMA Biologics by 192.2% during the third quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock valued at $10,567,000 after acquiring an additional 347,692 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of ADMA Biologics by 2.6% during the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company's stock worth $107,606,000 after purchasing an additional 137,989 shares during the period. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in shares of ADMA Biologics in the third quarter worth $1,047,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Trading Up 0.4 %

Shares of NASDAQ:ADMA traded up $0.08 during trading on Friday, reaching $21.31. The stock had a trading volume of 2,965,421 shares, compared to its average volume of 3,616,169. ADMA Biologics, Inc. has a 52 week low of $6.10 and a 52 week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm's fifty day moving average is $18.26 and its 200 day moving average is $18.23. The stock has a market cap of $5.04 billion, a price-to-earnings ratio of 76.11 and a beta of 0.53.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.